"id","uuid:ID","rationale","versionIdentifier","instanceType"
"StudyVersion_1","6aef43b4-6fb5-4ce7-8191-1e4acd79da39","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2","StudyVersion"
